Key facts
- Notable investors include Rock Sparrow Investment, Yisan Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Xitian (Shanghai) Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Xitian (Shanghai) Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xitian (Shanghai) Biotechnology
Provider of bioactive ingredient development designed to advance health and wellness through natural compounds. The company offers proprietary extraction technologies, high-purity bioactive substances, and customized formulation services, enabling nutraceutical, pharmaceutical, and cosmetic manufacturers to enhance product efficacy and support innovation in health-related applications.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Xitian (Shanghai) Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xitian (Shanghai) Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xitian (Shanghai) Biotechnology in its N-PORT filings yet. We sweep new filings monthly.